Short interest for Incyte gives investors a sense of the degree to which investors are betting on the decline of Incyte's stock. Short interest data is updated every two weeks.

Incyte Stock (NASDAQ:INCY), Short Interest Report

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

pharma lab worker ai

Analyst Color

Biotech

Equities

Large Cap

News

Health Care

Initiation

Analyst Ratings

Trading Ideas

General

INCY

Morgan Stanley Capital Protected Notes for S&P 500 Index

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.

Incyte Should Consider Significant Stock Buyback And Prioritize R&amp;D, Analyst Recommends

Novartis

Movers

Novartis&#39; €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B

people-95715_1280

Movers & Shakers

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of $92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer

Incyte Corp

TD Cowen analyst Marc Frahm maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Buy and lowers the price target from $88 to $80.

Price Target

TD Cowen Maintains Buy on Incyte, Lowers Price Target to $80

Truist Securities analyst Srikripa Devarakonda reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Buy and lowers the price target from $84 to $83.

Reiteration

Truist Securities Reiterates Buy on Incyte, Lowers Price Target to $83

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Market Perform and lowers the price target from $56 to $52.

BMO Capital Maintains Market Perform on Incyte, Lowers Price Target to $52

WIIM

Incyte shares are trading lower following a Q1 earnings miss.

Earnings

Guidance

Incyte Maintains Its 2024 Jakafi Net Product Revenue Guidance Of $2.69B-$2.75B, With Other Hematology/Oncology Net Product Revenues Of $325M-$360M

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) reported quarterly earnings of $0.64 per share which missed the analyst consensus estimate of $0.84 by 23.81 percent. This is a 72.97 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $880.889 which missed the analyst consensus estimate of $926.533 million by 100.00 percent. This is a 100.00 percent decrease over sales of $808.673 million the same period last year.

Earnings Misses

Incyte Q1 2024 Adj EPS $0.64 Misses $0.84 Estimate, Sales $880.889 Miss $926.533M Estimate

Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Outperform and lowers the price target from $92 to $84.

Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $84

Tuesday,&nbsp;Incyte Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)&nbsp;agreed to acquire&nbsp;Escient Pharmaceuticals&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38375064/incyte-announces-acquisition-of-escient-pharmaceuticals-and-its-pipeline-of-first-in-class-oral-mr" rel="noreferrer noopener">for $750 million</a>.
Escient&#8217;s pipeline includes EP262, a&nbsp;small&nbsp;molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), and EP547, a first-in-class oral MRGPRX4 antagonist.
&#8220;EP262 and EP547 are complementary additions to our portfolio, providing an opportunity to leverage our expertise, address the needs of patients with inflammatory diseases, and additional potential launch opportunities starting in 2029,&#8221; said Hervé Hoppenot, Incyte&#8217;s CEO.
With this update, Cantor Fitzgerald&nbsp;has initiated coverage on Incyte&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/INCY/analyst-ratings" rel="noreferrer noopener">with a Neutral rating</a>.&nbsp;
The Cantor analyst suggests that Incyte&#8217;s shares are undervalued primarily due to the cash and expected cash flow from Jakafi and Opzelura but expresses reservations about the company&#8217;s pipeline prospects.&nbsp;
However, Incyte&#8217;s stock has declined by 31% in the past year due to concerns about the 2029 patent expiration for Jakafi, its high-margin drug.
Both growth and value investors are hesitant to support the company&#8217;s current strategy. Value investors particularly note Incyte&#8217;s reluctance to return cash to shareholders. A&nbsp;major&nbsp;stock buyback before pivotal pipeline updates could alleviate concerns and bolster valuation.
The analyst questions Incyte&#8217;s ability to allocate over 40% of its revenue to R&amp;D&nbsp;efficiently&nbsp;and suggests prioritizing high-return pipeline candidates.&nbsp;
Cantor highlights the potential value of acquiring U.S. rights to&nbsp;MorphoSys AG&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>)&nbsp;pelabresib, which could&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36954650/novartis-agrees-to-acquire-german-blood-cancer-drug-developer-morphosys-for-2-7b" rel="noreferrer noopener">complement Jakafi</a>.&nbsp;
Despite optimism for certain pipeline assets like&nbsp;povorcitinib, the analyst remains cautious about others lacking differentiation or&nbsp;strong scientific&nbsp;rationale.
William Blair suggests that although the approval of another significant asset by the end of the decade will benefit Incyte in the long term, investors are seeking assets that can generate revenue before the patent exclusivity of Jakafi expires in 2028.&nbsp;
They maintain their positive outlook on Incyte, emphasizing that favorable Phase 3 results with&nbsp;povorcitinib&nbsp;in hidradenitis&nbsp;suppurativa&nbsp;in 2025 could alter perceptions and reaffirm their recommendation to Outperform.
Regarding the&nbsp;Escient deal,&nbsp;William Blair highlights the intriguing potential of the MRGPRX2 target. Initial data in chronic inducible urticaria suggests that EP262 complements the company&#8217;s existing inflammation and immunology franchises, tapping into significant market opportunities.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35902449/goldman-sachs-downgrades-incyte-amid-concerns-over-jakafi-studies-competitiveness" rel="noreferrer noopener">Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness</a>.
Price Action: INCY shares are up 0.25% at $52.05 at the last check Tuesday. 
Illustration of Phrama lab worker created with MidJourney.

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends

Across the recent three months, 10 analysts have shared their insights on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Incyte, presenting an average target of $70.8, a high estimate of $84.00, and a low estimate of $64.00. This current average has decreased by 1.21% from the previous average price target of $71.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1713891670_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Incyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Hold</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$81.00</td>
<td>-</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$64.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$68.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$84.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Incyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Incyte's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Incyte's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Incyte analyst ratings.</a>
<h2>All You Need to Know About Incyte</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Understanding the Numbers: Incyte's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Incyte displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 9.35%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Incyte's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 19.84%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Incyte's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 3.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Incyte Through Analyst Insights

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Neutral rating.

Cantor Fitzgerald Initiates Coverage On Incyte with Neutral Rating

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a definitive agreement under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist.
&nbsp;
Under the terms of the agreement, Incyte will acquire Escient and its assets for $750 million plus Escient&rsquo;s net cash remaining at the close of the transaction, subject to customary adjustments. The acquisition is subject to clearance under the Hart-Scott-Rodino Act, among other customary conditions, and will become effective promptly following the satisfaction or waiver of these conditions which is currently anticipated to be by the third quarter of 2024.

Incyte To Acquire Escient And Its Assets For $750M Plus Escient's Net Cash Remaining At The Close Of The Transaction, Subject To Customary Adjustments

China Medical System Holdings Limited (the &ldquo;Company&rdquo;, together with its subsidiaries, the &ldquo;Group&rdquo;) is pleased to announce that on 31 March 2024, the Group through a wholly-owned subsidiary of the Company&ndash; a dermatology medical aesthetic company (&ldquo;CMS Skinhealth&rdquo;) entered into a Collaboration and License Agreement (the &ldquo;License Agreement&rdquo;) with Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) (&ldquo;Incyte&rdquo;), a global biopharmaceutical company, for selective oral smallmolecule JAK1 inhibitor povorcitinib (the &ldquo;Product&rdquo;) for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN) and asthma and chronic spontaneous urticaria.

China Medical System Announced Collaboration And License Agreement With Incyte For Selective Oral Smallmolecule JAK1 Inhibitor Povorcitinib

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and maintains $65 price target.

RBC Capital Reiterates Sector Perform on Incyte, Maintains $65 Price Target

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Neutral and lowers the price target from $69 to $67.

B of A Securities Maintains Neutral on Incyte, Lowers Price Target to $67

Stifel analyst Stephen Willey reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Hold and maintains $68 price target.

Stifel Reiterates Hold on Incyte, Maintains $68 Price Target

In the preceding three months, 8 analysts have released ratings for Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $73.12, a high estimate of $84.00, and a low estimate of $64.00. This current average represents a 0.96% decrease from the previous average price target of $73.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1710259252_0_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Incyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$81.00</td>
<td>-</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$64.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$68.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$84.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Mara Goldstein</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Incyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Incyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Incyte's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Incyte analyst ratings.</a>
<h2>About Incyte</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Incyte: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Incyte's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 9.35%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 19.84%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Incyte's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 3.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

Sunday, Incyte Announced Results From A Phase 2 Study Of Povorcitinib (Incb54707), The Study Met Its Primary Endpoint With Improvement In Itch Compared To Placebo In Prurigo Nodularis

Sunday, Incyte Announced New Results From Phase 2 Study Of Ruxolitinib Cream (Opzelura) In Hidradenitis Suppurativa, The Study Met Its Primary Endpoint, Demonstrating Significant Reduction In Abscess, Inflammatory Nodule Count Versus Vehicle Control

<ul>
<li>Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream (Opzelura&#xAE;) in hidradenitis suppurativa and povorcitinib (INCB54707) in prurigo nodularis</li>
<li>Analyst and investor event to discuss key data presentations scheduled for Monday, March 11, 2024 at 9:00 a.m. PT / 12:00 p.m. ET</li>
</ul>
&nbsp;
Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.
"We are pleased to convene at this year's AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio," said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation &amp; Autoimmunity, Incyte. "Our presence at this year's meeting showcases Incyte's commitment to find solutions for patients where there continues to be critical unmet needs. We are excited to share clinical data evaluating ruxolitinib cream and povorcitinib in immune-mediated dermatologic conditions including atopic dermatitis, vitiligo, hidradenitis suppurativa and prurigo nodularis."
Key abstracts include:
Late-Breaking Oral Presentations
Prurigo Nodularis
Efficacy and Safety of Povorcitinib in Patients with Prurigo Nodularis: Results From a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study (Session: S050 – Late-Breaking Research: Session 2. Sunday, March 10, 2024, 4:00 p.m. ET)
Hidradenitis Suppurativa
Efficacy and Safety of Ruxolitinib Cream in Patients With Hidradenitis Suppurativa (Hurley Stage I and II): Results From a Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study (Session: S050 – Late-Breaking Research: Session 2. Sunday, March 10, 2024, 4:10 p.m. ET)
e-Posters with Mini Oral Presentation
Atopic Dermatitis
Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis in Children Aged 2–&lt;12 Years by Previous Medication History: Subgroup Analysis from the Randomized Phase 3 TRuE-AD3 Study (Abstract: #54214. Friday, March 8, 2024, 4:10 – 4:15 p.m. ET. Upper Level, Sails Pavilion, Poster Center 2)
e-Poster Exhibits
Atopic Dermatitis
Effect of Ruxolitinib Cream on Patient-Reported Outcomes (PROs) in Children Aged 2–&lt;12 Years with Atopic Dermatitis (AD): Results from a Randomized, Double-Blind, Vehicle-Controlled, Phase 3 Study (TruE-AD3) (Abstract: #49439)
Atopic Dermatitis (AD) Treatments Before and After Initiation of Ruxolitinib Cream: Analysis of a US Payer Claims Database (Abstract: #53102)
Real-World Clinical Experience with Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis (Abstract: #53107)
A Maximum-Use Trial of Ruxolitinib Cream in Children ≥2 to &lt;12 Years Old with Atopic Dermatitis (AD): Patient-Reported Outcomes (PROs) at Week 8 (Abstract: #54025)
Efficacy of Ruxolitinib Cream for Treatment of Atopic Dermatitis in Children Aged 2–&lt;12 Years by Baseline Clinical Characteristics: Subgroup Analysis from a Randomized Phase 3 Study (TRuE-AD3) (Abstract: #54147)
Maximum-Use Trials of Ruxolitinib Cream in Adults, Adolescents, and Children Aged 2 to &lt;12 Years with Atopic Dermatitis: Consistency of Safety, Pharmacokinetics, and Efficacy (Abstract: #54168)
Vitiligo
Serum Protein Biomarkers May Reveal Clues to Early Immune Activity Upon Ruxolitinib Cream Withdrawal in the TRuE-V Long-Term Extension Study (Abstract: #50342)
Efficacy of Povorcitinib for the Treatment of Vitiligo by Patient Demographics and Baseline Clinical Characteristics: Week 52 Subgroup Analysis from a Randomized, Placebo-Controlled, Phase 2b Clinical Trial (Abstract: #53962)
Correlation of Vitiligo Area Scoring Index with Vitiligo Extent Score-Plus Responses in a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Phase 2b Study (Abstract: #53971)
All abstract content will be available in the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feposters.aad.org%2F&amp;esheet=53904373&amp;newsitemid=20240304329736&amp;lan=en-US&amp;anchor=online+viewing+portal&amp;index=1&amp;md5=a80e4af72ff0d18809975ab0d42e13da">online viewing portal</a> and on-site at the viewing stations. They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.
More information regarding the 2024 AAD Annual Meeting can be found at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aad.org%2Fmember%2Fmeetings-education%2Fam24&amp;esheet=53904373&amp;newsitemid=20240304329736&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.aad.org%2Fmember%2Fmeetings-education%2Fam24&amp;index=2&amp;md5=38c2f3151bba7022c67fa3b532ebbada">https://www.aad.org/member/meetings-education/am24</a>.
Conference Call and Webcast
Incyte will host an in-person analyst and investor event on Monday, March 11, 2024, from 9:00-10:30 a.m. PT (12:00-1:30 p.m. ET) to discuss the key data presentations at AAD. The event will be webcasted and can be accessed via the Events and Presentations tab of the investor section of Incyte.com and it will be available for replay for 30 days.
Conference call details will be provided on our website.
About Opzelura&#xAE; (ruxolitinib) Cream 1.5%
Opzelura, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food &amp; Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.
In Europe, Opzelura (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States and Europe as Opzelura.
Opzelura and the Opzelura logo are registered trademarks of Incyte.
About Povorcitinib (INCB54707)
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for vitiligo, hidradenitis suppurativa (HS) and prurigo nodularis. Phase 3 studies in HS are also ongoing.

Events

New Data From Incyte's Dermatology Portfolio To Be Presented At The 2024 American Academy Of Dermatology Annual Meeting

Notable earnings before Tuesday's open

Incyte Q1 2024 Earnings Preview

Incyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75M

Incyte Corporation 2024 Q1 - Results - Earnings Call Presentation

Incyte Corporation (INCY) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Incyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/incy-stock-quote/">INCY</a>) just reported results for the first quarter of 2024.<ul><li>Incyte reported earnings per share of 64 cents. This was below the analyst estimate for EPS of 84 cents.</li><li>The company reported revenue of $880.89 million.</li><li>This was 4.93% worse than the analyst estimate for revenue of $926.53 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/incy-stock-earnings-incyte-for-q1-of-2024/">INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report) and Exelixis (EXEL...

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $60.00. The comp...

RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harmony Biosciences Holdings (HRMY – Research Report...

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Incyte (INCY – Research Report), reducing the price target to $80.00. Andrew B...

Incyte's Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip

ACIW

ADDYY

ANYYY

ARCB

BSBR

CECO

CPLP

CVLT

DLAKF

ETRN

EXEL

FELE

FNMA

GEHC

HEES

HRMY

HSBC

HUBB

IPGP

IVPAF

LDOS

LGIH

LKNCY

LODE

MASS

MBGAF

MLCO

MPLX

NAUT

NXRT

OCSL

OTLY

PCAR

RITM

SIRI

SITC

STLA

TMDX

Press Releases

New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte to Report First Quarter Financial Results

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Incyte Stock (NASDAQ:INCY), Short Interest Report

People Also Watch